Company Overview - Haemonetics Corporation provides blood management solutions to blood and plasma collectors, hospitals, and healthcare providers globally, offering integrated devices, information management, and consulting services to enhance clinical outcomes in the blood supply chain [11]. Investment Potential - Haemonetics is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid investment potential [12]. - The company has a Growth Style Score of B, forecasting a year-over-year earnings growth of 8.1% for the current fiscal year, with a recent upward revision in earnings estimates [12]. - The Zacks Consensus Estimate for Haemonetics has increased by $0.01 to $4.94 per share, and the company has an average earnings surprise of +6.8% [12]. Recommendation - With a strong Zacks Rank and favorable Growth and VGM Style Scores, Haemonetics is recommended for investors looking for growth opportunities [13].

分组1 - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum characteristics, helping investors identify securities with high potential for market outperformance [2][3] 分组2 - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E and Price/Sales, appealing to value investors [3] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected earnings and sales for long-term growth potential [4] - The Momentum Score assists investors in capitalizing on price trends by evaluating recent price changes and earnings estimate revisions [5] 分组3 - The VGM Score combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum, serving as a useful indicator alongside the Zacks Rank [6] - The Zacks Rank, a proprietary stock-rating model, utilizes earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [7][8] 分组4 - To optimize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while also considering the direction of earnings estimate revisions [9][10] - Haemonetics Corporation, which provides blood management solutions, is currently rated 3 (Hold) on the Zacks Rank but has a VGM Score of A and a Momentum Style Score of B, with shares increasing by 13.6% over the past four weeks [11][12] - Analysts have raised their earnings estimates for Haemonetics, with the Zacks Consensus Estimate increasing by $0.13 to $4.93 per share, indicating a positive outlook for the company [12][13]

Company Overview - Haemonetics Corporation provides blood management solutions globally, serving blood and plasma collectors, hospitals, and healthcare providers. The company's offerings include integrated devices, information management, and consulting services that enhance clinical outcomes across the blood supply chain [11]. Investment Insights - Haemonetics is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [12]. - The stock has a Momentum Style Score of B, with shares increasing by 50.5% over the past four weeks, suggesting strong recent performance [12]. - For fiscal 2026, three analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate rising by $0.07 to $4.87 per share. The company has an average earnings surprise of +6% [12]. Conclusion - With a strong Zacks Rank and favorable Momentum and VGM Style Scores, Haemonetics is positioned as a noteworthy option for investors [13].